News 07.11.2023 Switzerland, 07 November – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the successful completion of patient recruitment for the Phase 2 clinical trial of its lead product, denovoSkin™, in reconstructive surgery for both children and adults. This Phase 2 clinical trial...
News 05.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from its Phase 1 study of MP0317 in patients with advanced...
Events, Internal events
Event date: 21.11.2023
When: Tuesday, November 21st, 2023, 5 PM – 7 PM (including Apéro)
Where: Auditorium – Ground Floor, Wagistrasse 25, 8952 Schlieren
This event is perfect for those looking for tailored lab solutions. We will present our service offerings for startups and SMEs, and show you how you can save time and costs.
Your...
News 02.11.2023 Schlieren / Zurich, Switzerland – November 2, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures...
News 02.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase...